Efficacy and Safety of Certolizumab Pegol Over Four Years in Psoriatic Arthritis Patients with and without Concomitant use of DMARDS

Authors

Robert G. Cooper
Jessica Walsh
Alice B. Gottlieb, New York Medical CollegeFollow
Bengt Hoepken
Tommi Nurminen
Philip J. Mease

Document Type

Abstract

Publication Date

4-2018

DOI

10.1093/rheumatology/key075.386

Journal Title

Rheumatology

Department

Dermatology

Recommended Citation

Cooper, R. G., Walsh, J., Gottlieb, A. B., Hoepken, B., Nurminen, T., & Mease, P. J. (2018). Efficacy and Safety of Certolizumab Pegol Over Four Years in Psoriatic Arthritis Patients with and without Concomitant use of DMARDS. Rheumatology, 57 (Suppl. 3), 162. https://doi.org/10.1093/rheumatology/key075.386